Telmisartan and Amlodipine — Class III drug recall D-0049-2027
Ongoing recall by Viatris, Inc., reported 2026-10-28, distributed nationwide. Superpotent Drug: potential for the Telmisartan content in these lots to exceed specifications
| Recall number | D-0049-2027 |
|---|---|
| Product type | Drug |
| Classification | Class III |
| Status | Ongoing |
| Voluntary or mandated | Voluntary |
| Recalling firm | Viatris, Inc., Morgantown, WV, United States |
| Recall initiated | 2026-10-01 |
| Classified | 2026-10-16 |
| Reported by FDA | 2026-10-28 |
| Distributed | Nationwide (US) |
| Reason classes | potency |
| NDC | 00378-1075, 00378-1075-93, 00378-1076, 00378-1076-93, 00378-1077, 00378-1077-93, 00378-1078, 00378-1078-93 |
| Lot numbers | 3228113, 3228114, 3228115, 3228120, 3228121 |
| Expiration dates | 2026-10-31, 2026-11-30 |
Product
Telmisartan and Amlodipine, Tablets, USP, 40mg/5 mg, 30-count Bottle, Rx only, Manufactured for: Mylan Pharmaceuticals Inc., Morgantown, WV 26505 USA, Made in India, NDC 0378-1075-93.
Reason for recall
Superpotent Drug: potential for the Telmisartan content in these lots to exceed specifications
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-0049-2027. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-11-03. Not affiliated with or endorsed by FDA. Not medical or legal advice.